Literature DB >> 8828620

Phenylketonuria: treatment in adolescence and adult life.

D P Brenton1, A C Tarn, J C Cabrera-Abreu, M Lilburn.   

Abstract

In our clinic the decision on whether to continue with dietary treatment of phenylketonuria or not is left to each adolescent and adult patient after the advantages and disadvantages, as discussed in this paper, of continuing diet have been presented to them. As a result 61 of 132 patients have stopped diet or declined to restart and only 4 of them have phenylalanine values below 1000 mumol/l. Seventy-one patients have remained on diet or started again with phenylalanine values below 1000 mumol/l in 58 of them. This series of 132 excludes women who returned to diet to conceive.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8828620     DOI: 10.1007/pl00014261

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  22 in total

1.  Neurological deterioration in young adults with phenylketonuria.

Authors:  R J Allen
Journal:  Lancet       Date:  1990-10-13       Impact factor: 79.321

2.  Vitamin B12 deficiency in adolescents and young adults with phenylketonuria.

Authors:  W B Hanley; A Feigenbaum; J T Clarke; W Schoonheyt; V Austin
Journal:  Lancet       Date:  1993-10-16       Impact factor: 79.321

3.  Valine, isoleucine, and leucine. A new treatment for phenylketonuria.

Authors:  H K Berry; R L Brunner; M M Hunt; P P White
Journal:  Am J Dis Child       Date:  1990-05

4.  Spasticity and white matter abnormalities in adult phenylketonuria.

Authors:  P A McCombe; D B McLaughlin; J B Chalk; N N Brown; J J McGill; M P Pender
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

5.  Neurological deterioration in adult phenylketonuria.

Authors:  D Villasana; I J Butler; J C Williams; S M Roongta
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

6.  The natural history of untreated phenylketonuria over 20 years.

Authors:  D B Pitt; D M Danks
Journal:  J Paediatr Child Health       Date:  1991-06       Impact factor: 1.954

7.  In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy.

Authors:  E J Novotny; M J Avison; N Herschkowitz; O A Petroff; J W Prichard; M R Seashore; D L Rothman
Journal:  Pediatr Res       Date:  1995-02       Impact factor: 3.756

8.  Neurological deterioration in young adults with phenylketonuria.

Authors:  A J Thompson; I Smith; D Brenton; B D Youl; G Rylance; D C Davidson; B Kendall; A J Lees
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

9.  Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man.

Authors:  W Krause; M Halminski; L McDonald; P Dembure; R Salvo; D Freides; L Elsas
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

10.  Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function.

Authors:  F Güttler; H Lou
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

View more
  2 in total

1.  MR imaging-based volumetry in patients with early-treated phenylketonuria.

Authors:  Nadine H Pfaendner; Gitta Reuner; Joachim Pietz; Gregor Jost; Dietz Rating; Vincent A Magnotta; Alexander Mohr; Bodo Kress; Klaus Sartor; Stefan Hähnel
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

2.  Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes.

Authors:  Erin L MacLeod; Sally T Gleason; Sandra C van Calcar; Denise M Ney
Journal:  Mol Genet Metab       Date:  2009-08-08       Impact factor: 4.797

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.